乳酸驱动YY1 K183乳酰化介导急性肺损伤上皮屏障功能障碍
该研究在ARDS患者样本和多种ALI小鼠模型中验证乳酸升高,发现糖酵解抑制剂2-DG或沉默LDHA可减轻肺损伤和肺泡上皮屏障功能障碍,而外源乳酸加重病理。机制上乳酸促进Tip60依赖的YY1 K183乳酰化,抑制PGC-1α转录,导致线粒体稳态紊乱和屏障破坏。靶向该位点的穿透肽和甘草酸苷可缓解损伤。
要点
- ALI中乳酸蓄积通过YY1 K183乳酰化破坏肺泡上皮屏障
- 抑制糖酵解或沉默LDHA可减轻ALI小鼠肺损伤
- 靶向YY1 K183乳酰化的穿透肽和甘草酸苷具转化潜力
核心结论
- 乳酸驱动的YY1 K183乳酰化破坏PGC-1α介导的线粒体质量控制与上皮屏障稳定性,干预该轴是ALI/ARDS潜在治疗方向。
研究设计与样本
- 研究在多个ARDS患者外周样本和肺组织及多种ALI小鼠模型中验证乳酸丰度升高。
- 采用2-DG耗竭内源乳酸、气管内注射AAV9-shLdha沉默肺LDHA、外源乳酸补充及YY1-K183R突变体体内回补实验。
主要发现
- ARDS患者样本和ALI小鼠模型中乳酸丰度显著升高。
- 2-DG耗竭内源乳酸减轻肺损伤和肺泡上皮屏障功能障碍,外源乳酸补充加重病理表现。
- 气管内注射AAV9-shLdha沉默肺LDHA重现2-DG的保护表型。
- 乳酸促进Tip60依赖的YY1第183位赖氨酸乳酰化,抑制PGC-1α转录,导致线粒体稳态紊乱和肺泡上皮屏障破坏。
- YY1-K183R突变体体内回补实验验证该位点乳酰化在LPS触发ALI进展中的致病作用。
关键数值与推荐
- YY1 K183乳酰化由Tip60依赖机制催化,抑制PGC-1α转录表达。
- K183靶向穿透肽和甘草酸苷均抑制YY1 K183乳酰化、恢复PGC-1α表达和线粒体功能,减轻肺水肿、炎症浸润和细胞凋亡。
临床怎么用
- 提示监测乳酸及YY1 K183乳酰化水平可能有助于评估ALI/ARDS上皮屏障损伤。
- 糖酵解抑制或LDHA沉默在动物模型中显示保护作用,但临床转化需进一步验证。
- K183靶向穿透肽和甘草酸苷为ALI/ARDS提供了候选干预策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Elevated lactate levels in lung tissue are a distinct hallmark of acute lung injury (ALI), but the biological functions of glycolytic reprogramming and lactate-derived protein modification in damaged alveolar epithelial cells remain poorly elucidated. In the present study, we validated markedly increased lactate abundance in peripheral samples and lung tissues of multiple ARDS patients and multiple ALI mouse models. Administration of glycolysis inhibitor 2-DG to deplete endogenous lactate effectively mitigated lung injury and alveolar epithelial barrier dysfunction, whereas exogenous lactate supplementation significantly worsened these pathological manifestations. Genetic silencing of pulmonary LDHA via intratracheal injection of AAV9-shLdha successfully reproduced the protective phenotypes conferred by 2-DG treatment. Mechanistically, accumulated lactate facilitated Tip60-dependent lactylation modification of YY1 at lysine 183. Biochemical assays confirmed that YY1 K183 lactylation inhibited the expression of PGC-1α at transcriptional level, further causing mitochondrial homeostasis disorder and destruction of alveolar epithelial barrier. In vivo rescue experiments using lactylation-deficient YY1-K183R mutant verified the essential pathogenic role of this site-specific lactylation in LPS-triggered ALI progression. Additionally, we established two feasible translational therapeutic strategies, including K183-targeted cell-penetrating peptide and glycyrrhizin screened from compound libraries. Both candidates efficiently suppressed YY1 K183 lactylation, restored PGC-1α expression and mitochondrial function, and relieved pulmonary edema, inflammatory infiltration and cell apoptosis. In summary, lactate-driven YY1 K183 lactylation disrupts PGC-1α-mediated mitochondrial quality control and epithelial barrier stability. Intervening this lactate-YY1 lactylation axis provides a reliable and promising therapeutic direction for clinical treatment of ALI and ARDS.
引用
- Li N, Liu Y, Gao M, et al. YY1 lactylation mediates epithelial barrier dysfunction during acute lung injury. Eur Respir J. 2026. PMID: 42601184. doi:10.1183/13993003.02717-2025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。